136 patents
Page 7 of 7
Utility
Compositions and methods for inhibition of the JAK pathway
10 Feb 20
Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.
Yan Chen, Vanessa Taylor, Hui Li, Rajinder Singh
Filed: 23 May 18
Utility
TGF-Beta Inhibitors
29 Jan 20
Todd Kinsella, Marina Gelman, Hui Hong, Ihab S. Darwish, Rajinder Singh, Jiaxin Yu, Robert M. Borzilleri, Upender Velaparthi, Peiying Liu, Chetan Padmakar Darne, Hasibur Rahaman, Jayakumar Sankara Warrier
Filed: 20 Mar 19
Utility
Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds
15 Jan 20
The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases.
Rajinder Singh, Ankush Argade, Hui Li, Somasekhar Bhamidipati, David Carroll, Catherine Sylvain, Jeffrey Clough, Holger Keim
Filed: 20 Mar 19
Utility
Ampk-activating Heterocyclic Compounds and Methods for Using the Same
15 Jan 20
Dane Goff, Donald Payan, Rajinder Singh, Simon Shaw, David Carroll, Yasumichi Hitoshi
Filed: 24 Jun 19
Utility
Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses
15 Jan 20
The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, salts and hydrates of the prodrugs, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.
Somasekhar Bhamidipati, Rajinder Singh, Thomas Sun, Esteban Masuda
Filed: 11 Jun 19
Utility
ACVR2A-SPECIFIC Antibody and Method of Use Thereof
18 Dec 19
The present disclosure provides antibodies that specifically bind to and block signaling by ACVR2A, i.e., ACVR2A but not ACVR2B, as well as methods for using the same.
Todd M. KINSELLA, Ramesh BHATT, Kristen BALTGALVIS
Filed: 26 Mar 18
Utility
Tyrosine Kinase Inhibitors
18 Dec 19
Ihab Darwish, Jiaxin Yu, Rao Kolluri, Sacha Holland
Filed: 28 May 19
Utility
Prodrugs of NRF2 Activating Compounds and Uses Thereof
4 Dec 19
Aspects of the present disclosure include prodrugs of compounds that activate Nrf2.
Jiaxin Yu, Beth Fernandez, Gary Park, Ihab Darwish
Filed: 13 May 19
Utility
Fumarate analogs and uses thereof
2 Dec 19
Aspects of the present disclosure include compounds that find use for the treatment of a variety of autoimmune and inflammatory diseases and disorders.
Matthew Duncton, Somasekhar Bhamidipati, Jiaxin Yu, Ihab Darwish, Rajinder Singh
Filed: 20 Sep 17
Utility
2,4-PYRIMIDINEDIAMINE Compounds and Their Uses
27 Nov 19
The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
Rajinder Singh, Ankush Argade, Donald G. Payan, Susan Molineaux, Sacha J. Holland, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li, Alexander B. Rossi
Filed: 18 Jun 19
Utility
Amide Compounds and Method for Making and Using
27 Nov 19
Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors.
Kin Tso, Hui Li, Yan Chen, Rose Yen, Vanessa Taylor, Thilo Heckrodt, Rajinder Singh, Simon Shaw
Filed: 1 Aug 19
Utility
Compositions and methods for inhibition of the JAK pathway
18 Nov 19
Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.
Hui Li, Thilo J. Heckrodt, Yan Chen, Darren John McMurtrie, Vanessa Taylor, Rajinder Singh, Pingyu Ding, Rose Yen
Filed: 7 Feb 18
Utility
Axl Inhibitors for Use In Combination Therapy for Preventing, Treating or Managing Metastatic Cancer
6 Nov 19
This invention is directed to methods of preventing, treating or managing cancer, preferably metastatic cancer, in a patient.
Yasumichi Hitoshi, Sacha Holland, Donald G. Payan
Filed: 11 Mar 19
Utility
Tetrazolones as a carboxylic acid bioisosteres
21 Oct 19
The present disclosure provides compounds that include a tetrazolone derivative of a carboxyl group of an active agent.
Matthew Duncton, Rajinder Singh
Filed: 7 Jun 17
Utility
Tyrosine kinase inhibitors
7 Oct 19
Sacha Holland, Rajinder Singh, Somasekhar Bhamidipati, Pingyu Ding, Rao Kolluri, Ihab Darwish, Esteban Masuda, Jiaxin Yu
Filed: 3 Oct 18
Utility
Irak Inhibitors and Method for Making and Using
2 Oct 19
Disclosed embodiments concern interleukin receptor associated kinases (IRAK) inhibitors, such as oxazole compounds, and compositions comprising such inhibitors.
Hui Li, Thilo Heckrodt, Yan Chen, Ryan Kelley, Darren McMurtrie, Kin Tso, Vanessa Taylor, Rajinder Singh, Rose Yen, Jack Maung
Filed: 17 Jun 19